UK markets closed

Eupraxia Pharmaceuticals Inc. (EPRX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.9400+0.1900 (+6.91%)
At close: 04:00PM EDT
2.8500 -0.09 (-3.06%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.7500
Open2.7900
Bid2.7300 x 2000
Ask2.8200 x 100
Day's range2.7900 - 2.9400
52-week range2.4800 - 3.5000
Volume8,715
Avg. volume32,725
Market cap104.73M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano

  • PR Newswire

    Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.

  • PR Newswire

    Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.